On June 14, 2016, the journal Gut Pathogens released a new study entitled “RHB-104 Triple Antibiotics Combination in Culture is Bactericidal and Should be Effective for Treatment of Crohn’s Disease Associated with Mycobacterium paratuberculosis.” The researchers from the University of Central Florida (including Dr. Saleh Naser) found that the raw active ingredients used in RHB-104 worked together in combination to inhibit the growth of 16 Mycobacterium avium paratuberculosis (MAP) strains and 19 other mycobacterial species.

Read the Full Article

To all of the fathers out there: We hear you and acknowledge your love and strength in whatever health battle you are fighting. We support you. We care.

Read the Full Article

In this age of organic food, chemical free products, farmer’s markets and going green, it’s no wonder that Dietzia spp. C79793-74 is generating great interest among Crohn’s disease patients. After all, if this emerging probiotic therapy could curtail the symptoms of Crohn’s disease as well as, or even better than, conventional therapies but without the side effects, it may well become the future of Crohn’s treatment. While human research and trials need to be completed, Dietzia has shown promise in cattle infected with Johne’s disease.

With new information emerging about this bacterial species, we thought our readers would enjoy this timely overview. We are honored to introduce the man who discovered benefits of Dietzia spp. C79793-74, Dr. Robert E. Click.

Read the Full Article

Some of you may have seen these recent news articles regarding MAP and Crohn’s disease. For those of you who missed it, here’s a brief recap. I particularly enjoyed listening to the two new interviews given by Prof. Thomas Borody.

Read the Full Article